Doctor of Podiatric Medicine Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Tommy Saing

Podiatrist, Foot & Ankle Surgery Tucson, AZ Doctor of Podiatric Medicine

NPI 1669049003 CMS profile 11643299

2308 N Rosemont Blvd, Tucson, AZ 85712

Open in the dashboard

General payments

$3,935

85 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tommy Saing of Tucson, AZ is reported in the CMS Open Payments database as having received $3,935 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,158 51
2024 General $1,777 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tommy Saing
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Tommy Saing were reported at $2,158. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Tommy Saing Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $0 $389 $118–$1,406 $163
2020 $0 $191 $62–$691 $114
2021 $0 $329 $104–$1,341 $132
2022 $0 $419 $125–$1,611 $149
2023 $0 $377 $128–$1,164 $160
2024 $1,777 $394 $134–$1,168 $164
2025 $2,158 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Stryker Corporation $1,923 25 payments
  2. Smith+Nephew, Inc. $443 23 payments
  3. Globus Medical, Inc. $214 4 payments
  4. Averitas Pharma Inc. $213 5 payments
  5. MIMEDX Group, Inc. $210 6 payments
  6. Austin Medical Ventures Inc $154 1 payment
  7. MedShape, Inc. $150 1 payment
  8. Medical Device Business Services, Inc. $137 1 payment
  9. Arteriocyte Medical Systems, Inc. $102 1 payment
  10. Orthofix Medical, Inc. $76 3 payments
  11. Other $314 15 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $2,814 79 payments
  2. Travel and Lodging $985 5 payments
  3. Education $137 1 payment
Products named General payments · program years 2024–2025
  1. ORTHOLOC 3DI $1,063 15 payments
  2. PROSTEP $605 5 payments
  3. Senza $214 4 payments
  4. Qutenza $213 5 payments
  5. ORTHOLOC 2 LAPIFUSE $158 4 payments
  6. Synthecure $154 1 payment
  7. COLLAGENASE SANTYL $152 16 payments
  8. STRATAFIX $137 1 payment
  9. Magellan $102 1 payment
  10. PROSTEP MICA $98 1 payment
  11. Other $678 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

26

Median for Podiatry: 160

Drug cost

$367

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Monohydrate Generic 13 $232
Mupirocin Generic 13 $135

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $147
$147 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $17
$17 — —
Tirosint
  • IBSA Pharma Inc. $9
$9 — —
Licart
  • IBSA Pharma Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record